BerandaANTH • OTCMKTS
add
Anthera Pharmaceuticals Inc
Tutup sebelumnya
$0,00010
Kapitalisasi pasar
2,62Â rb USD
Volume Rata-Rata
23,93Â rb
Rasio P/E
-
Hasil dividen
-
Bursa utama
OTCMKTS
Berita pasar
Keuangan
Laporan Pendapatan
Pendapatan
Laba bersih
| (USD) | 2017info | Perubahan Y/Y |
|---|---|---|
Pendapatan | — | — |
Biaya operasional | 7,94Â jt | -28,30% |
Laba bersih | -26,87Â jt | 51,60% |
Margin laba bersih | — | — |
Penghasilan per saham | -3,80 | 70,53% |
EBITDA | -36,15Â jt | 36,48% |
Tarif pajak efektif | — | — |
Neraca
Total aset
Total liabilitas
| (USD) | 2017info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,20Â jt | -89,46% |
Total aset | 3,67Â jt | -84,35% |
Total liabilitas | 9,17Â jt | -13,70% |
Total ekuitas | -5,50 jt | — |
Saham yang beredar | 23,40 jt | — |
Harga terhadap nilai buku | -0,00 | — |
Tingkat pengembalian aset | -167,77% | — |
Tingkat pengembalian modal | -619,42% | — |
Arus Kas
Perubahan kas bersih
| (USD) | 2017info | Perubahan Y/Y |
|---|---|---|
Laba bersih | -26,87Â jt | 51,60% |
Kas dari operasi | -36,90Â jt | 24,57% |
Kas dari investasi | — | — |
Kas dari pembiayaan | 18,25Â jt | -22,58% |
Perubahan kas bersih | -18,65Â jt | 28,58% |
Arus kas bebas | -23,15Â jt | 18,17% |
Tentang
Anthera Pharmaceuticals, Inc. is an American biopharmaceutical company focused on developing and commercializing products to treat serious conditions associated with cystic fibrosis, inflammation and autoimmune diseases. Liprotamase, Anthera's leading drug candidate which is being developed for exocrine pancreatic insufficiency is currently in Phase 3 clinical trials, and A-623 for the treatment of IgA nephropathy is currently in Phase 2 clinical trial. Wikipedia
Didirikan
2004
Kantor pusat
Situs
Karyawan
21
